Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-07-10 | Nanexa | Sommarbrev från Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-10 | Nanexa | Summer letter from Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Nanexa | Bulletin from Nanexa’s Annual General Meeting 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Nanexa | Kommuniké från årsstämma i Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Nanexa | Nanexa har slutfört den planerade rekryteringen till Fas 1-studien av NEX-20 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-09 | Nanexa | Nanexa has completed the planned recruitment to the Phase 1 study of NEX-20 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-01 | Nanexa | Nanexa skriver kontrakt med internationellt ledande CRO inom diabetes för fas I-studie med NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-01 | Nanexa | Nanexa signs contract with leading international diabetes CRO for Phase I study with NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Nanexa signs contract with leading international diabetes CRO for Phase I study with NEX-22Nanexa AB today announced that the company is engaging the contract research organization (CRO) Profil, in Neuss, Germany, ahead of the upcoming start of a phase I study with NEX-22, a monthly depot of liraglutide for the treatment of type 2 diabetes and ultimately obesity. Profil is highly specialized in early clinical studies in diabetes and obesity, and has an excellent global reputation for conducting clinical research in these two indications. Profil is a full-scale CRO specializing in early clinical research and translational research in diabetes and obesity. Since its inception in 1999, the company has been engaged in numerous clinical research studies with some of the world’s largest pharmaceutical companies. For its research in these indications, the company has up to 65 beds at its clinic and a team of more than 330 employees, over 25 of whom are physicians. “We are thrilled to be involved in the development of a once-monthly formulation of liraglutide using Nanexa’s advanced drug delivery system PharmaShell®. A GLP-1 analog that only needs to be injected once a month has the potential not only to further facilitate diabetes therapy and enhance patient compliance, but may improve tolerability and efficacy. In close collaboration with the experienced management team and the outstanding expert advisors from Nanexa, we set up a lean development plan to be able to demonstrate proof-of-concept already in early stages of development”, says Dr. Tim Heise, Lead Scientist and Co-Founder of Profil. ”Germany is by far one of the largest pharmaceutical markets in Europe and in the world, and is the country in Europe that, with its pricing system, allows sales from day one when a new drug is approved in the EU. The fact that we are already placing our first clinical research study with NEX-22 in Germany, with a CRO that has such a good global reputation in these two metabolic diseases, ensures high quality data with efficient execution for a possible future license partner within the framework of NEX-22”, says David Westberg, CEO of Nanexa. The NEX-22 project is now in the preclinical phase and Nanexa announced earlier this year that a first animal study showed a release of liraglutide over 28 days. Further preclinical studies are now underway, which preliminarily confirm these results. ”The NEX-22 project is very exciting and undoubtedly fills a great medical need, to make it easier for patients to avoid frequent injections of their drug. A depot preparation over a month is in many ways ideal for patients with diabetes or obesity and it also simplifies things for healthcare providers and pharmacies. After all my years in the pharmaceutical industry, I have also realized the importance of establishing good knowledge of a drug’s advantages and disadvantages in the research clinics in the countries where it is first launched and begins to be used on a larger scale.”, says Bengt Gustavsson, Director of Clinical Research and Medical Affairs at Nanexa. The phase I study of NEX-22 expected to be ready to start around the end of 2023. |
||||
2023-05-22 | Redeye | Redeye: Nanexa - Moments of truth closing in | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Nanexa | Kallelse till årsstämma i Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Nanexa | Notice of Annual General Meeting in Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-05 | Emergers | Emergers: Equity Research | NANEXA: Solid progress in development into 2023, with funding needs on the horizon | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Nanexa | Nanexa publishes interim report for January – March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Nanexa | Nanexa publicerar delårsrapport för januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Nanexa | Nanexa publicerar årsredovisning för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-03 | Nanexa | Nanexa publishes annual report for 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-03-23 | Nanexa | NEX-22 preclinical data shows controlled release of liraglutide for one month | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-23 | Nanexa | Prekliniska data av NEX-22 bekräftar kontrollerad frisättning av liraglutid i en månad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-23 | Emergers | Emergers: NANEXA: 90 Second Pitch with CEO David Westberg | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Redeye | Redeye: Nanexa Q4 2022 - A Stronger Case | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-17 | Emergers | Emergers: Equity Research | NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-16 | Nanexa | Nanexa publishes year-end report for 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-16 | Nanexa | Nanexa publicerar bokslutskommuniké för 2022 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-02-15 | Nanexa | Inbjudan till presentation av Nanexas bokslutskommuniké och Q4-rapport | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-15 | Nanexa | Invitation to presentation of Nanexa’s year-end report and Q4-report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-08 | Nanexa | Nanexa participates at the 4th annual “Beyond Medicines’ Barriers Meeting”, arranged by the International Myeloma Foundation | Analyser | Ladda ner | Visa Stäng |
|
||||
2023-02-08 | Nanexa | Nanexa deltar på 4th annual “Beyond Medicines’ Barriers Meeting”, arrangerat av International Myeloma Foundation | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-23 | Emergers | Emergers: Equity Research | NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-21 | Nanexa | Inbjudan till nyhetskommentar med anledning av Nanexas nyhetssläpp den 21 december 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-21 | Nanexa | Invitation to commentary regarding Nanexa's press release on 21 December 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-21 | Nanexa | Nanexa signs an exclusivity and evaluation agreement worth SEK 46.1 million and completes a directed share issue of SEK 17.2 million to Novo Nordisk | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-21 | Nanexa | Nanexa tecknar ett exklusivitets- och utvärderingsavtal värt 46,1 MSEK och genomför en riktad emission till Novo Nordisk om 17,2 MSEK | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-06 | Nanexa | Nanexa har startat Fas 1-studien med NEX-20 enligt plan | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-12-06 | Nanexa | Nanexa has started the Phase 1 study of NEX-20 according to plan | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-16 | Nanexa | Nanexa AB och VitriVax, Inc. har nått en lösning på patentintrångsprocessen | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-16 | Nanexa | Nanexa AB and VitriVax, Inc. have resolved the patent infringement lawsuit | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-14 | Nanexa | Nanexa receives approval to start clinical trial with NEX-20 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-14 | Nanexa | Nanexa erhåller godkännande att starta klinisk studie med NEX-20 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-10 | Nanexa | Valberedning inför Nanexa AB (publ) årsstämma 2023 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-10 | Nanexa | Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-26 | Emergers | Emergers: Equity Research | NANEXA: Charging to enter triple clinical trials in the coming year | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-25 | Nanexa | Nanexa publishes interim report for January – September 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-25 | Nanexa | Nanexa publicerar delårsrapport för januari-september 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-24 | Nanexa | Inbjudan till presentation av Nanexas Q3-rapport 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-21 | Nanexa | Nanexa tecknar utvärderingsavtal med läkemedelsbolag specialiserat inom ögonområdet | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-10-21 | Nanexa | Nanexa signs evaluation agreement with a Speciality Pharma company | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-27 | Nanexa | Nanexa AB och Vitrivax, Inc har nått en överenskommelse i alla väsentliga delar | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-27 | Nanexa | Nanexa AB and Vitrivax, Inc reach agreement in principle | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-19 | Emergers | Emergers: NANEXA Equity Research Case Video Summary | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-16 | Emergers | Emergers: Equity Research | NANEXA: New project NEX-22 to add significant daily benefits for 50m patient market | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-15 | Nanexa | Nanexa startar produktprojektet NEX-22 som adresserar en enorm marknad | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-09-15 | Nanexa | Nanexa launches NEX-22 product project to address a huge market | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-30 | Nanexa | Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-30 | Nanexa | Nanexa signs evaluation agreement with a Global Pharmaceutical Company | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-29 | Redeye | Redeye: Nanexa - Our Q2 Comment | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Nanexa | Nanexa publishes interim report for January – June 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-26 | Nanexa | Nanexa publicerar delårsrapport för januari-juni 2022 | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-25 | Nanexa | Nanexa receives extended GMP-certificate for the new pilot plant | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-25 | Nanexa | Nanexa erhåller utökat GMP certifikat för den nya pilotanläggningen | Analyser | Ladda ner | Visa Stäng |
|